Research ArticleBasic Sciences
In Vitro and In Vivo Targeting of Radiolabeled Monovalent and Divalent Haptens with Dual Specificity Monoclonal Antibody Conjugates: Enhanced Divalent Hapten Affinity for Cell-Bound Antibody Conjugate
Jean-Marc Le Doussal, Marie Martin, Emmanuel Gautherot, Michel Delaage and Jacques Barbet
Journal of Nuclear Medicine August 1989, 30 (8) 1358-1366;
Jean-Marc Le Doussal
Marie Martin
Emmanuel Gautherot
Michel Delaage
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
In Vitro and In Vivo Targeting of Radiolabeled Monovalent and Divalent Haptens with Dual Specificity Monoclonal Antibody Conjugates: Enhanced Divalent Hapten Affinity for Cell-Bound Antibody Conjugate
Jean-Marc Le Doussal, Marie Martin, Emmanuel Gautherot, Michel Delaage, Jacques Barbet
Journal of Nuclear Medicine Aug 1989, 30 (8) 1358-1366;
In Vitro and In Vivo Targeting of Radiolabeled Monovalent and Divalent Haptens with Dual Specificity Monoclonal Antibody Conjugates: Enhanced Divalent Hapten Affinity for Cell-Bound Antibody Conjugate
Jean-Marc Le Doussal, Marie Martin, Emmanuel Gautherot, Michel Delaage, Jacques Barbet
Journal of Nuclear Medicine Aug 1989, 30 (8) 1358-1366;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer
- Introduction to monoclonal antibodies
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
- Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts
- Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
- Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
- A Divalent Hapten-Peptide Induces Apoptosis in Human Non-Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 x Anti-Hapten Bispecific Antibodies
- Bispecific Antibody Pretargeting of Radionuclides for Immuno-Single-Photon Emission Computed Tomography and Immuno-Positron Emission Tomography Molecular Imaging: An Update
- Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
- Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide
- Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
- Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
- Imaging Experimental Atherosclerotic Lesions in ApoE Knockout Mice: Enhanced Targeting with Z2D3-Anti-DTPA Bispecific Antibody and 99mTc-Labeled Negatively Charged Polymers
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
- Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft
- Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- The Direct Route May Not Be the Best Way to Home
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates
- Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
- Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
- Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- A 3-Step Pretargeting Strategy to Image Infection
- Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
- Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate